Drug Interactions in the Treatment of Depression in Patients With Ischemic Heart Disease
J Clin Psychiatry 2012;73(12):e1475-e1477
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Depression and ischemic heart disease commonly coexist, and each can worsen the course and outcome of the other. Depression is commonly treated with selective serotonin reuptake inhibitors (SSRIs), and ischemic heart disease patients commonly receive aspirin and/or clopidogrel. SSRIs can interact with these antiplatelet treatments in 2 ways. First, SSRIs can increase the risk of bleeding events with antiplatelet therapy; this risk may be diminished by the administration of a proton pump inhibitor. Second, fluoxetine and fluvoxamine may inhibit the metabolic activation of clopidogrel, thereby potentially diminishing the efficacy of clopidogrel. Issues related to these drug interactions are discussed.